Table 3.
Risk factors for HHV6 reactivation after autologous SCT*.
| HHV-6 positive (n = 10) | HHV-6 negative (n = 16) | P | |||
|---|---|---|---|---|---|
| Age | 57 (49–67) | 53 (35–63) | n.s. | ||
| Male | 7 (70%) | 6 (37.5%) | n.s. | ||
| Female | 3 (30%) | 10 (62.5%) | n.s. | ||
| Median time from diagnosis to SCT, months (range) | 8.5 (6–28) | 7 (5–19) | n.s. | ||
|
| |||||
| Induction regimen* | VD | TD | VD | TD | |
| 8 (44%) | 2 (25%) | 10 (54%) | 8 (75%) | n.s. | |
|
| |||||
| Median accumulative steroid dosage, mg (range) | 880 (640–1600) | 640 (320–4320) | 0.038 | ||
| Pretransplant lymphocyte count (cells/μL) | 1045 | 730 | 0.24 | ||
*Calculation represents the proportion of HHV-6 infection in screened patients that were treated with the same induction regimen (VD or TD, resp.).